ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Rexin-G Returns To The Big Apple: Clinical Trials For Pancreatic Cancer And Breast Cancer Open In Manhattan
Epeius Biotechnologies
Corporation announced the expansion of clinical trials using
intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan,
New York. Rexin-G is the world's first tumor-targeted genetic medicine that
is designed to seek out and destroy both primary tumors and metastatic
cancers that have spread throughout the body. Clinical data from on-going
studies in Los Angeles, California, indicating dose-dependent tumor control
rates and survival benefits with no major toxicity in Rexin-G-treated
patients prompted the extension of these clinical trials to the East Coast.
Rexin-G has gained orphan drug status from the U.S. FDA for three clinical
indications: pancreatic cancer, osteosarcoma and soft tissue sarcoma.
The New York clinical trials will be conducted at the Bruckner Oncology
Center in Manhattan, New York with Howard W. Bruckner, M.D. as the
Principal Investigator. Dr. Bruckner is a board certified medical
oncologist who trained at Yale University School of Medicine and performed
research at the NIH with specialists and collaborative groups. Dr. Bruckner
is internationally renowned for his work in pancreatic, breast,
gastrointestinal, colon, and ovarian cancers and was the first medical
oncologist to treat patients with Rexin-G for advanced pancreatic cancer in
the United States (Int'l J Oncol 2006). He has served as an Expert
Consultant and Safety Monitor for the National Surgical Adjuvant Project
for Breast and Bowel Cancers Project (NSABP) sponsored by the National
Cancer Institute. For further information concerning these clinical trials
in New York, please go to http://www.clinicaltrials.gov and search
Epeius-sponsored protocols C07-104 and C07-105.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held
biopharmaceutical company dedicated to the advancement of genetic medicine
with the development and commercialization of its proprietary targeted
delivery systems. To learn more about Rexin-G and Epeius' pipeline of
proprietary compounds currently available for outlicensing and clinical
development, please visit us at http://www.epeiusbiotech.com.
Epeius Biotechnologies Corporation
http://www.epeiusbiotech.com
Rexin-G revine la Big Apple: În studiile clinice pancreatic cancer ºi cancer de sân deschis în Manhattan - Rexin-G Returns To The Big Apple: Clinical Trials For Pancreatic Cancer And Breast Cancer Open In Manhattan - articole medicale engleza - startsanatate